



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

BLAKE et al

Atty. Ref.: 39-187

Serial No.: 09/367,261

Group Art Unit:

Filed: August 13, 1999

Examiner:

For: **DRUG TARGETING**

\* \* \* \* \*

August 27, 1999

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Hon. Commissioner of Patents  
and Trademarks  
Washington, DC 20231

Sir:

Attached is a PTO-1449 Form listing the documents cited in the International Search Report that should be substituted for that filed August 13, 1999. The attached Form corrects the publication number of the Senju Pharma Co. European case.

Respectfully submitted,

**NIXON & VANDERHYE, P.C.**

By Mary J. Wilson  
Mary J. Wilson  
Reg. No. 32,955

MJW:tat

1100 North Glebe Road  
8<sup>th</sup> Floor  
Arlington, Virginia 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100



INFORMATION DISCLOSURE  
CITATION

ATTY. DOCKET NO.

39-187

SERIAL NO.

09/367,261

APPLICANT


BLAKE et al

(Use several sheets if necessary)

FILING DATE

August 13, 1999

GROUP



## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS		SUBCLASS	FILING DATE IF APPROPRIATE
	5086068	2/1992	Raleigh et al				
	5387692	2/1995	Riley et al				

## FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	TRANSLATION		
			CLASS	SUBCLASS	YES
0 650 763	6/1995	EP			
WO 96 25147	8/1996	PCT			

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Oellinger et al, "Study on the redox properties of naphthazarin (5,8-dihydroxy-1,4-naphthoquinone) and its glutathionyl conjugate in biological reactions: one- and two-electron enzymic reduction", <i>CHEMICAL ABSTRACTS</i> , VOL. 112, NO. 11, 12 March 1990, Columbus, Ohio, US; and <i>ARCH. BIOCHEM. BIOPHYS.</i> (1989).
	Firestone et al, "Nitro heterocycle reduction as a paradigm for intramolecular catalysis of drug delivery to hypoxic cells", <i>J. MED. CHEM.</i> (1991), 34(9).
	Chikhale et al, "Tumor targeted prodrugs: Redox-activation of conformationally constrained, bioreductive melphalan prodrugs", <i>EIGHTY-EIGHTH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH</i> , San Diego, California, USA, April 12-16, 1997. <i>PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING</i> (38) (0). 1997. 432-433.
	Mehta et al, "Potential bioreductively activated hypoxia probes and post-irradiation radiosensitizers related to NITP", <i>ANTI-CANCER DRUG DES.</i> (1995), 10(3), 227-41.
	Hodgkiss et al, "Pharmacokinetics and binding of the bioreductive probe for hypoxia, NITP: effect of route of administration", <i>BR. J. CANCER</i> , vol. 72, 1995, pages 1462-1468.
	Berglund, "Bioreductive Heterosubstituted Quinone Antitumor Drug Delivery Agents", <i>DATABASE DISSABS</i> , 1987.

\*Examiner Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)